Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario

On October 31, 2024, Anavex Life Sciences Corp. (NASDAQ: AVXL ) stock rallied on new data from the phase 2b/3 trial in Alzheimer’s patients that was presented at the CTAD conference in Madrid. Though there is something toI am a long-term investor focused on growth markets, AI and biotech opportunities in my more volatile portfolio. I try to look for undervalued and under-the-radar stocks with serious potential and good scientific or other background. My ambition here is to cover stocks with considerable gro ...